Home › Funds › Vivo Capital, LLC › CRVS
Vivo Capital, LLC position in CRVS
CORVUS PHARMACEUTICALS INC · Health Care
Vivo Capital, LLC reported holding 2,805,816 shares of CRVS (CORVUS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$32.3M, representing 3.67% of its reported portfolio and ranking #10 among its reported holdings. Vivo Capital, LLC has disclosed CRVS holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Vivo Capital, LLC's CRVS position evolved
Vivo Capital, LLC first disclosed a stake in CRVS in Q3 2024 at 1,497,268 shares (US$7.9M). The position peaked in Q2 2026 at 2,805,816 shares, worth US$41.9M. Across 9 filings, Vivo Capital, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 2,805,816 shares valued at US$32.3M. Notable position changes include a 49% increase in Q4 2024 (shares fell 41% over the following quarter), a 26% increase in Q1 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 1.50M | $7.91M | New |
| Q4 2024 | 2.23M | $11.95M | Add |
| Q1 2025 | 2.23M | $7.11M | Hold |
| Q2 2025 | 2.23M | $8.94M | Hold |
| Q3 2025 | 2.23M | $16.47M | Hold |
| Q4 2025 | 2.23M | $17.21M | Hold |
| Q1 2026 | 2.81M | $41.05M | Add |
| Q2 2026 | 2.81M | $41.92M | Hold |
| Q3 2026 | 2.81M | $32.32M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRVS and 13F data
CRVS (CORVUS PHARMACEUTICALS INC) is a Health Care company. 66 other funds we track also report a position in CRVS — the largest reported positions include ORBIMED ADVISORS LLC (US$107.0M), ADAMS STREET PARTNERS LLC (US$48.9M), PERCEPTIVE ADVISORS LLC (US$39.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRVS
- ORBIMED ADVISORS LLC 7.17M sh · $107.05M · Q2 2026
- ADAMS STREET PARTNERS LLC 3.28M sh · $48.94M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.67M sh · $39.85M · Q2 2026
- Deep Track Capital, LP 2.49M sh · $37.23M · Q2 2026
- BRAIDWELL LP 2.13M sh · $31.77M · Q2 2026
- Foresite Capital Management VI LLC 1.83M sh · $27.36M · Q2 2026
- Boxer Capital Management, LLC 1.10M sh · $16.43M · Q2 2026
- Catalio Capital Management, LP 1.08M sh · $16.15M · Q2 2026
- Eversept Partners, LP 747.99K sh · $11.18M · Q2 2026
- DCF Advisers, LLC 641.50K sh · $7.39M · Q3 2026
- Nextech Invest Ltd. 450.00K sh · $6.72M · Q2 2026
- Blue Owl Capital Holdings LP 358.60K sh · $4.13M · Q3 2026
More on Vivo Capital, LLC
FAQ
How long has Vivo Capital, LLC held CRVS?
Vivo Capital, LLC has disclosed CRVS holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Vivo Capital, LLC's current position in CRVS?
As of Q3 2026, Vivo Capital, LLC holds 2.81M shares of CRVS (CORVUS PHARMACEUTICALS INC), valued at $32.32M, representing 3.67% of its reported portfolio and ranking #10.
Has Vivo Capital, LLC been buying or selling CRVS?
In the latest 13F filing (Q3 2026), Vivo Capital, LLC held unchanged its position in CRVS. The position peaked in Q2 2026 at 2.81M shares.
Which other funds hold CRVS?
Other major institutional holders of CRVS include ORBIMED ADVISORS LLC, ADAMS STREET PARTNERS LLC, PERCEPTIVE ADVISORS LLC, among 66 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.